#julie hashiguchi

[miravayl]

15.03.24

#Mira-Marathon | Danny Phantom

Animation Series Name: Danny Phantom | Season 2 | (2005); Production studios: Nickelodeon Animation Series, Billionfold; Director by: Butch Hartmanz, Wincat Alcala, Gary Conrad, Julie Hashiguchi, Kevin Petrilak, Ken Bruce, Richard Bowman, Sean Dempsey, Daniel de la Vega; Screenwriters: Brian Hogan, Sib Ventress, Marty Isenberg, Bob Boyle, Mark Banker, Mark Drop, Amy Keating Rogers, Kevin Sullivan, David Silverman, Stephen Sustarsic, Ellen Lichtwardt Goodchild, Steve Marmel, George Goodchild, Scott D. Peterson, Butch Hartman, Matt Wayne; Starring: David Kaufman, Grey Griffin, Rickey D'Shon Collins, Rob Paulsen, Kath Soucie; Genres: Science Fiction, Fantasy, Action; Running Time: One series – 22 minutes | All series – 7 hours 20 minutes;

The second season of Danny Phantom continues the emotional and exciting adventures of the main character. It is packed with action, humor and exploration of more complex themes. Character development and raised stakes add depth to the story. While there are slight flaws in some episodes, overall this season is a great addition to the first and will appeal to fans of the series.

My rating: 8/10

#mira marathon #danny phantom #animation series #season 2 #2005 #nickelodeon animation series #billionfold #science fiction #fantasy #action #-1 hour #7 hours #8/10 #david kaufman #grey griffin #brian hogan #wincat alcala #sib ventress #gary conrad #marty isenberg #julie hashiguchi #bob boyle #kevin petrilak #mark banker #ken bruce #mark drop #richard bowman #amy keating rogers #sean dempsey #kevin sullivan

[hauntedbystorytelling]

Part of : ホトトギス Kleine koekoek (Gackelkuckuck, Lesser Cuckoo), Hashiguchi Goyô, 1904 - 1905

print maker: Asai Chû / print maker: Hashiguchi Goyô

Number 6 of volume 8 (March 1905) of the literary monthly Hototogisu: cover with black frogs in gray water and orange water lily leaves. letterpress printing / color woodcut

Number 11 of volume 8 (July 1905) of the literary monthly ホトトギス Hototogisu: cover with gray frogs in green water and dark green water lily leaves. letterpress printing / color woodcut

#Hototogisu #1900s #illustration #frogs #water plants #pond #Kleine koekoek #rijksmuseum #Asai Chu #Hashiguchi Goyo #japanese artist #japanese art #Gackelkuckuck #Lesser Cuckoo #Cucut menut #Cuckoo #ホトトギス

[yourdailyqueer]

Ryōsuke Hashiguchi

Gender: Male

Sexuality: Gay

DOB: 13 July 1962 

Ethnicity: Japanese

Occupation: Director, screenwriter, producer, actor

#Ryōsuke Hashiguchi #Ryosuke Hashiguchi #qpoc #lgbt #lgbtq #male #gay #1962 #japanese #asian #poc #director #screenwriter #producer #actor

[factrugby3]

Class room of the Professional Anime's 2nd Period Premieres on This summer some

New aesthetic also revealed The particular official website with regard to the television cartoons of Syougo Kinugasa's Classroom of the particular Elite (Y? koso Jitsuryoku Shij? Shugi no Ky? shitsu e) light book series revealed about Monday that the show's second time of year will premiere in July 4. Typically the show's official Facebook account also unveiled a new image. Crunchyroll will supply the anime mainly because it airs under the particular title Classroom regarding the Elite 2.

The first season's directors Seiji Kishi and Hiroyuki Hashimoto are returning like chief directors, together with Yoshihito Nish? ji (first season's starting sequence, Maji para Otaku na English! Ribbon-chan: Eigo sobre Tatakau Mah? You will need? jo, Seven Sensory faculties of the Re'Union) because the credited overseer at Lerche. Dragon Ball Super Gogoanime (first season's episode scripts, Eliminating Bites, Rumble Garanndoll) is now overseeing the particular series scripts, and even Kazuaki Morita is definitely back to develop the characters. Masaru Yokoyama is now making the music, became a member of by Kana Hashiguchi (A3! Season Fall months & Winter, A3! Season Spring and Summer, Black Fox). Singer ZAQ is returning from the particular first season to be able to perform the brand new opening theme tune "Dance in the Game. " In nessun caso Fuchigami is vocal the new stopping theme song "Hito Jibai. " Typically the first season started in July 2017. Crunchyroll streamed typically the series, and Funimation streamed a language dub. The anime in addition getting a 3 rd season in 2023. The second and even third seasons can adapt the unique story's complete first-year-student arc. Crunchyroll details the first time: Kiyotaka Ayanokoji just enrolled at Tokyo Koudo Ikusei High school graduation, where it's declared 100% of college students go on to be able to college or locate employment. But they ends up found in Class 1-D, which often is full involving each of the school's problem children. What's even more, every month, the school awards students details with a funds value of 100, 500 yen, and the particular classes use a laissez-faire policy through which talking, sleeping, and also sabotage are permitted in the course of class. 30 days later on, Ayanokoji, Horikita, and even the students of Class D understand the truth associated with the system set up within their school? Kadokawa published the first volume of typically the original light story series in May possibly 2015. Seven Waters is releasing the novel series and even its manga edition in English. The particular Classroom in the Top notch: Year 2 (Y? koso Jitsuryoku Shij? Shugi no Ky? shitsu e: 2-nen Sei Hen) lighting novels can be a sequel to the key light novel sequence. The first new amount of the fresh second year sequence debuted in Japan in January 2020 as the 15th overall book within the series (the collection has three "in-between" short story anthology volumes prior to the start of minute year arc). Seven Seas is also liberating the sequel novels in English. Supply: Classroom from the Top notch anime's Twitter accounts and website

#Dragon Ball Super Gogoanime

[mia-japanese-korean]

Woman After a Bath, Hashiguchi Goyō, July 1920, Minneapolis Institute of Art: Japanese and Korean Art

nude seated woman, seen from back, looking over her PR shoulder; blue floral cloth over woman's lap Portrait of Kodaira Tomi 小平とみ. Size: 17 1/4 x 11 7/16 in. (43.82 x 29.05 cm) (image) 23 × 19 × 1 1/2 in. (58.42 × 48.26 × 3.81 cm) (outer frame) Medium: Woodblock print; ink and color on paper with mica

https://collections.artsmia.org/art/62503/

#hashiguchigoyō #minneapolisinstituteofart #museumarchive #artsmia

[kentootv]

「グッド・ドクター」 Good Doctor

DORAMA DETAILS

Title: グッド・ドクター

Title (english): Good Doctor

Genre: Medical drama

Episodes: –

Broadcast network: Fuji TV

Release date: July 12, 2018

Air time: Thursday 22:00

Theme song: –

PLOT

Shindo Minato (Yamazaki Kento) is autistic and has savant syndrome. His memory is amazing although he was difficulty communicating with other people. As a child he dreamed of becoming a doctor. He meet Doctor Shiga Akira and he wanted to become a paediatric surgeon. Shiga Akira was really surprised by his memory of the human organs and he decided to support Shindo Minato in achieving his dream. Then he suggests Minato to work in the pediatric surgery at the hospital where he works. Minato eventually enters the world of pediatric surgery as a resident.

TRAILER

CAST

Yamazaki Kento (山﨑賢人) as Shindo Minato (新堂湊)

Ueno Juri as Seto Natsumi

Fujiki Naohito as Takayama Seiji

Totsugi Shigeyuki as Mamiya Keisuke

Nakamura Yuri as Togo Michi

Hamano Kenta as Hashiguchi Taro

Itao Itsuji as Inoguchi Ryunosuke

Emoto Akira as Shiga Akira

PRODUCTION STAFF

Screenwriter: Tokunaga Yuichi (徳永友一), Okita Haruka (大北はるか)

Producer: Fujino Ryota (藤野良太), Kinjo Ayaka (金城綾香)

Assistant Producer: Nishisaka Mizuki (西坂瑞城)

Director: Kanai Hiro (金井紘), Aizawa Hideyuki (相沢秀幸)

Music: –

WEBSITE

Official Homepage: fujitv.co.jp/gooddoctor

Official Twitter: @GoodDoctor2018

source: asianwiki, wikipedia

#TV drama #Good Doctor #グッド・ドクター #dorama #jdrama #山﨑賢人 #Yamazaki Kento

[otakunews01]

Hataraku Saibou TV anime Teaser PV. Airs July 2018 (David Production). 

Key Visual

Kenichi Suzuki (JoJo's Bizarre Adventure, Drifters) is directing the anime at David Production, and Yuuko Kakihara (Tsuki ga Kirei, Persona 4 The Animation) is in charge of series composition, and both Suzuki and Kakihara will pen the scripts. Takahiko Yoshida (Welcome to the NHK, Yowamushi Pedal) is designing the characters and is also credited as chief animation director, while Kenta Mimuro is credited as cell character designer, prop designer, and animation scene animation director. Keiko Tamaki is credited for sub-character design. Kenichiro Suehiro (Re:Zero, Girls' Last Tour) is composing the music at MAYUKO.

Other staff include:

Art Setting: Yoshihiro Sono, Koji Hashiguchi

Art: Atelier PLATZ

Color Setting: Aiko Mizuno

Director of Photography: Yuki Oshima

3D CG Director: Yutaka Nakajima

Editor: Kiyoshi Hirose (editz)

Sound Director: Jin Aketagawa

Sound Production: MAGIC CAPSULE

Produce: Yuma Takahashi

Animation Producer: Go Wakamatsu

Production: Aniplex, Kodansha, David Production

#Hataraku Saibou #anime

[pkjd]

Akane Shimizu’s Hataraku Saibou manga will be receiving a TV anime adaptation. It will premiere in July 2018.

-Synopsis-

“The average human body contains about 60 trillion cells, and each of them has work to do! But when you get injured, viruses or bacteria invade, or when an allergic reaction flares up, everyone from the silent but deadly white blood cells to the brainy neurons has to work together to get through the crisis!”

-Staff-

Director: Kenichi Suzuki

Series Composition: Yuuko Kakihara 

Script: Kenichi Suzuki, Yuuko Kakihara

Character Designer, Chief Animation Director: Takahiko Yoshida

Sub Character Designer: Keiko Tamaki

Prop Designer: Kenta Mimuro

Music: Kenichiro Suehiro

Art Setting: Yoshihiro Sono, Koji Hashiguchi

Art: Atelier PLATZ

Color Setting: Aiko Mizuno

Director of Photography: Yuki Oshima

3D CG Director: Yutaka Nakajima

Editor: Kiyoshi Hirose (editz)

Sound Director: Jin Aketagawa

Sound Production: MAGIC CAPSULE

Produce: Yuma Takahashi

Animation Producer: Go Wakamatsu

Animation Production: David Production

Source: http://hataraku-saibou.com/

#hataraku saibou #cells at work! #anime

[standbyyou5]

all around the world

(J-Drama) Good Doctor

September 22, 2018

Genre : Medical drama

Based on : Good Doctor

by Park Jae-bum

Written by : Yuichi Tokunaga

Haruka Okita

Directed by : Hiro Kanai

Hideyuki Aizawa

Ending theme : Hikari by Androp

Country of origin : Japan

Original language : Japanese

No. of episodes : 10

Production

Producer : Fujino Ryota

Kinjo Ayaka

Production location : Japan

Running time : Thursdays at 10pm

Release

Original network : Fuji TV

Original release : July 12 – September 13, 2018

Related shows : Good Doctor

Cast :

Kento Yamazaki as Minato Shindo

Junta ito as young Minato

Juri Ueno as Natsumi Seto

Naohito Fujiki as Seiji Takayama

Supporting :

Akira Emoto as Akira Shiga

Yuri Nakamura as Michi Togo

Kenta Hamano as Taro Hashiguchi

Itsuji Itao as Ryunosuke Inoguchi

Shigeyuki Totsugi as Keisuke Mamiya

Kodai Asaka as Nakajima

Daigo Matsui as Marui

Ryosuke Ikeoka as Nonomura

Risaki Matsukaze as Iyo Morishita

Drama ini adalah adaptasi dari drama korea berjudul Good Doctor tahun 2013

drama koreanya saya tidak nonton, maaf terlalu lama di flash back jadi saya ga kuat nonton versi korea :/

yg versi US juga saya nonton sedikit2 doang di fox channel karena saya ga hafal jadwal tayangnya, saya cuma hafal jadwal tayang the walking dead di fox channel hahaha

Menceritakan tentang Minato Shindo yg seorang autis savant syndrome tapi memiliki ingatan luar biasa. Bagaimana mungkin seorang autis bisa menjadi dokter? Ini hanyalah drama televisi, bukalah imajinasi anda untuk menonton ini hahaha

Minato adalah dokter bedah anak, dia mempunyai kakak yg meninggal saat masih kecil, itulah yg membuat Minato ingin menjadi dokter bedah anak. Minato agak sulit berkomunikasi dengan orang2.

Awalnya banyak dokter yg meragukan Minato. Yaiyalah bagaimana mungkin seorang autis bisa menjadi dokter bedah anak? Selama menonton ini, saya tidak melihat Minato mengoperasi pasien, dia memiliki mata yg tajam. Bisa melihat apa yg tidak bisa dilihat dokter lain mengenai kelainan organ dll (jadi ingat doctor house)

Drama ini lebih di fokuskan kepada permasalahan pasien yg cukup menarik diikuti, tidak bertele2 dan langsung kepada masalah

Berhasilkah Minato merubah semua pandangan dokter terhadapnya?

Yamazaki kento disini mengambil peran yg sangat berbeda dibanding drama2 sebelumnya, good job dia mencoba peran lain😄

Review ini juga saya tulis di fairytophia425.blogspot.com

[angelojocd198-blog]

Get Healthy Stay Healthy With Chiropractic

Presently I work a lot with centers, like your dental expert. This puts undue tension on our spinal column and muscles, which can cause back discomfort. I also got shooting pain from my neck down in my elbows and wrists.

Chiropractic Marketing Changes Permanently On July 15Th

How typically have you heard individuals state, "One day I felt fine, and then the next day I was just."? Probably enough that you do not even recognize the absolute absurdity of that statement. Except for extreme traumas, such as cars and truck accidents, significant falls, gunshot injuries, poisoning, and so on, people do not unexpectedly ended up being ill. Illness does not take place spontaneously. Little injuries, long-lasting abuse and neglect, though undetectable initially, take their toll on the body over a time period. By the time the first signs appear, the body has currently been malfunctioning for some amount of time-- typically years.

How To Minimize Or Remove Back Labor In Future Pregnancies

Feeling Numb or Muscle Weakness - This could be experienced along the nerve path gonstead chiropractic in the leg or foot. You could experience discomfort in one part of the leg and pins and needles in another.

Details: Peachtree Vehicle Bath is a brilliant, white area in the garage of the Peachtree Lenox Building. Call 678-755-0202 for an appointment. It's a short walk to Hashiguchi, Jr. Sushi Bar situated at 3400 Around Lenox Roadway on the https://www.slp.wa.gov.au/industrial/indgaz.nsf/77D02C464B46162448257EBC00048753/$File/v70Feb01.pdf back side of the old Swiss Hotel, now the Westin Buckhead. Call 404-841-9229.

Just How Much Chiropractic Care Does Your Back Requirement?

There is no need for you to be wary of bringing your baby to a chiropractic doctor. The gonstead chiropractic offered to infants is mild which includes trigger point therapy and a little massage. To tell you honestly, there is nothing to fret.

Don't chiropractic adjustment use 'a stone' unless you are 'a Goliath.' Choose the best rake for your size. Some rakes are huge and uncomfortable, even heavy. Discover a rake that feels comfortable to you. Buying a rake that fits you can be an enjoyable way to jump-start your project.

How To Enhance Your Chiropractic Collections At The Front Desk

I walked alone in a little park along the Mississippi River towards dusk. I had simply walked from the barren downtown, where I stopped briefly to read a historical marker outside the Raddison Hotel. It was the only marker I saw in the downtown proper. Turns out Davenport was the site of the very first chiropractic change, in 1895.

[miravayl]

09.03.24

#Mira-Marathon | Danny Phantom

Animation Series Name: Danny Phantom | Season 1 | (2003); Production studios: Nickelodeon Animation Series, Billionfold; Director by: Butch Hartmanz, Wincat Alcala, Gary Conrad, Julie Hashiguchi, Kevin Petrilak, Ken Bruce, Richard Bowman, Sean Dempsey, Daniel de la Vega; Screenwriters: Brian Hogan, Sib Ventress, Marty Isenberg, Bob Boyle, Mark Banker, Mark Drop, Amy Keating Rogers, Kevin Sullivan, David Silverman, Stephen Sustarsic, Ellen Lichtwardt Goodchild, Steve Marmel, George Goodchild, Scott D. Peterson, Butch Hartman, Matt Wayne; Starring: David Kaufman, Grey Griffin, Rickey D'Shon Collins, Rob Paulsen, Kath Soucie; Genres: Science Fiction, Fantasy, Action; Running Time: One series – 22 minutes | All series – 7 hours 20 minutes;

"Danny Phantom" is an American animated series from 2004 about the adventures of 14-year-old Danny Fenton, who becomes half-human, half-ghost. He uses his new abilities to fight other ghosts and protect the city of Amity Park. The season is fun, dynamic and interesting for children and adults, with great animation and an exciting plot.

My rating: 8/10

#mira marathon #danny phantom #animation series #season 1 #2003 #nickelodeon animation series #billionfold #david kaufman #grey griffin #rickey d'shon collins #rob paulsen #kath soucie #-1 hour #science fiction #fantasy #action #7 hours #8/10 #butch hartmanz #brian hogan #sib ventress #marty isenberg #wincat alcala #gary conrad #bob boyle #julie hashiguchi #mark banker #kevin petrilak #mark drop #ken bruce

[gamezonemalang]

Hai Gamezoners,

Drama jepang “Good Doctor” merupakan hasil remake dari Drama Korea “Good Doctor” dari KBS2 tahun 2013 lalu. jadi untuk alur cerita tak jauh berbeda dengan aslinya.

Drama Jepang “Good Doctor” atau yang dikenal juga dengan judul asli “Guddo Dokuta” akan di siarkan di Fuji TV mulai 12 Juli 2018 pukul 22.00 setiap hari Kamis. Drama ini akan bercerita tentang kisah dokter yang memiliki sindrom ingatan yang luar biasa namun sulit untuk berkomunikasi dengan orang sekitarnya.

Aktor terkenal Kento Yamazaki yang akan menjadi pemain utama dalam serial drama “Good Doctor” versi Jepang. Yamazaki Kento sebelumnya bermain di drama seri “Death Note” 2015, “A Girl & Three Sweethearts” dan yang terbaru adalah “Todome no Kiss” tahun 2018.

SINOPSIS Good Doctor :

Minato Shindo (Kento Yamazaki) memiliki sindrom savant. Ingatannya luar biasa, tetapi dia kesulitan berkomunikasi dengan orang lain.

Ketika Minato Shindo masih kecil, dia bermimpi menjadi seorang dokter. Dia bertemu dengan Dokter Akira Shiga dan dia ingin menjadi seorang ahli bedah anak. Akira Shiga terkejut oleh memori 7 tahun dari organ manusia dan dia memutuskan untuk mendukung Minato Shindo dalam mencapai mimpinya. Akhirnya, Minato Shindo lulus dari sekolah kedokteran dan lulus ujian nasional untuk praktisi medis.

Sekarang, Akira Shiga bekerja sebagai direktur di sebuah rumah sakit besar. Dia menyarankan kepada Minato Shindo untuk bekerja di departemen bedah anak di rumah sakit tempat dia bekerja.

Detail Tentang Drama Good Doctor :

Judul : Good Doctor Judul Lainnya : Guddo Dokuta/ グッド ドクター Genre : Drama, Medical, Romance Episodes : 10 (to be confirm) Sutradara : Hiro Kanai dan Hideyuki Aizawa Penulis Naskah : Yuichi Tokunaga dan Haruka Okita Stasiun Channel : Fuji TV Negara : Jepang Di tayangkan pada : 12 Juli 2018, setiap hari Kamis pukul 22.00

Detail Daftar Pemain Good Doctor :

Kento Yamazaki berperan sbg Minato Shindo Juri Ueno berperan sbg Natsumi Seto Naohito Fujiki berperan sbg Seiji Takayama Shigeyuki Totsugi berperan sbg Keisuke Mamiya Yuri Nakamura berperan sbg Michi Togo Kenta Hamano berperan sbg Taro Hashiguchi Itsuji Itao berperan sbg Ryunosuke Inoguchi Akira Emoto berperan sbg Akira Shiga

This slideshow requires JavaScript.

Baca juga :  Sinopsis Let’s Eat 3 : Drama Korea Terbaru Juli 2018

Jangan lupa Like dan Follow terus SosMed kami karena bakalan banyak info menarik seputar Movie, Game, BoxOffice, Anime, dan banyak lagi info lainya.

www.GAMEZONE.co.id SALES – SERVICE – RENTAL

INTERNET CAFE & PLAYSTATION RENTAL Jl. MT Haryono 73, Ruko Dinoyo Indah Kavling 1 Malang 65145 (200m barat laut Univesitas BrAwijaya) HP/SMS/Whatsapp: [phone] Telp: 0341-5075630 Email: [email protected] FB: Gamezone Internet Cafe & PlayStation Rental IG: Gamezonemalang Twitter: @GamezoneMalang Blog: www.gamezone.co.id/blog/ GPS: -7° 56.777′, 112° 36.736 Google Maps : https://goo.gl/rcyxAL

BRANCH : LANDUNGSARI Jl. Raya Tlogomas No.29G, Ruko Tlogomas Indah II Kav. 7 65144 (Depan UMM Kampus 3 Malang) HP/SMS/Whatsapp: [phone]

STORE HEADQUARTER Jl. MT Haryono 73, Ruko Dinoyo Indah Kavling 6 Malang 65145. Tel/Fax: [phone] HP/SMS/Whatsapp: [phone] BBM: 5AE8828A FB: Gamezone.webstore Email/Yahoo Messenger: [email protected] GPS Coordinate: -7° 56.777′, 112° 36.736′

BRANCH : Bondowoso – 0341-552719, BBM: 542364E5 MATOS – 0341-559121, BBM: 52644EFF

RENTAL HEADQUARTER Jl. MT Haryono 73, Ruko Dinoyo Indah Kavling 6 Malang 65145. Tel: [phone] HP/SMS/Whatsapp: [phone] BBM: 51A172D5 IG: gamezonemoviebank Email/Yahoo Messenger: [email protected]

BRANCH : Landungsari 085746934636, BBM: 57B8FDE2 Bondowoso 0341-552719, BBM: 542364E5

Come, Play, and Feel the Difference !

Sinopsis Good Doctor : Drama Remake Jepang Terbaru Juli 2018 #InternetCafe #ps3 #ps4 #rentalps #gamezonemalang #Gamezone #malang #sewapsmalang #infomalang #infomalangraya #infomalangku #infomalangnet #infomalangkota #rentalpsmalang #infodrama #dramajuli Hai Gamezoners, Drama jepang “Good Doctor” merupakan hasil remake dari Drama Korea “Good Doctor” dari KBS2 tahun 2013 lalu.

#2018 #detail #Drama #Drama Korea #juli #sinopsis

[recentanimenews]

Cells are Busy on Their Duties in TV Anime Cells at Work! 2nd Key Visual

For the upcoming TV premiere in Japan on July 7, the official website for TV anime adaptation of Akane Shimizu's Hataraku Saibou/Cells at Work! manga is updated with a second key visual featuring its main human cell characters who are busy on their duties.

  The TV anime adaptation is directed by Kenichi Suzuki (Drifters, JoJo's Bizarre Adventure), alongside series composition writer Yuko Kakihara (as the moon, so beautiful, Chihayafuru) and character designer Takahiko Yoshida (Big Windup!, Yowamushi Pedal). David Production (Inu x Boku SS, JoJo's Bizarre Adventure), previously produced an anime CM to promote the manga's fifth tankobon volume released in August 2017, again works on anime production.

    2nd key visual with the announcement for the TV premiere schedule

    Textless version

    Two additional voice cast are also announced:

  Shoya Chiba (Hayato Akiyama in The Idolm@ster SideM) as B Cell

    Mamiko Noto (Moriko Morioka in Recovery of an MMO Junkie) as the narrator

      Main voice cast:

   Neutrophil: Tomoaki Maeno (Hiro Hayami in KING OF PRISM by PrettyRhythm)

 Erythrocite: Kana Hanazawa (Kosaki Onodera in Nisekoi)

 Macrophage: Kikuko Inoue (Belldandy in Oh My Goddess)

 Killer T Cell: Daisuke Ono (Jyushimatsu in Mr.Osomatsu)

 Platelet: Maria Naganawa (Kamuri Sengoku in Slow Start) 

 Helper T Cell: Takahiro Sakurai (Osomatsu Matsuno in Mr.Osomatsu) as

 Regulatory T Cell: Saori Hayami (Miyuki Shiba in The Irregular at Magic High School)  

 Eosinophil: M.A.O (Hinako Sakuragi in Hinako Note) 

 Dendritic Cell: Nobuhiko Okamoto (Katsuki Bakugo in My Hero Academia) 

    OP song "Mission! Ken-Ko-Dai-Ichi" is sung by Erythrocite (Kana Hanazawa), Neutrophil (Tomoaki Maeno),

Killer T Cell (Daisuke Ono), and Macrophage (Kikuko Inoue).

  The ED song "CheerS" is performed by two-member anison unit ClariS. The song will be released as 

thei 20th single on August 15.

    TV anime 1st key visual

     Main Staff:

 Director: Kenichi Suzuki (Drifters, JoJo's Bizarre Adventure)

 Series Composition Writer: Yuko Kakihara (as the moon, so beautiful,Chihayafuru)

 Screenplay: Kenichi Suzuki, Yuko Kakihara

 Character Designer Takahiko Yoshida (Big Windup!, Yowamushi Pedal)

 Cell Character Designer/Prop Designer/Action Animation Director: Kenta Mimuro

 Sub Character Designer: Keiko Tamaoki

 Chief Animation Director: Takahiko Yoshida, Keiko Tamaoki

 Arts: Atelier Platz

 Art Designer: Yoshihiro Sono, Kouji Hashiguchi

 Color Designer: Aiko Mizuno

 Director of Photography: Yuki Oshima

 3DCG Director: Yutaka Nakajima

 Editor: Kiyoshi Hirose (editz)

 Sound Director: Kawahito Akita

 Sound Production Magic Capsule

 Music Kenichiro Suehiro, MAYUKO

 Produce: Yuma Takahashi

 Animation Producer: Tsuyoshi Wakamatsu

 Anime Production: David Production

 Production: Aniplex, Kodansha, David Production

    Source: Aniplex press release 

  © Akane Shimizu/Kodansha, Aniplex, david production

  By: [email protected]

#Anime #News #Latest in Anime News by Crunchyroll!

[cleopatrarps]

Shire willing to back $64 billion Takeda bid, market signals doubts

LONDON/NEW YORK/TOKYO (Reuters) – Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year.

FILE PHOTO: Vitamins made by Shire are displayed at a chemist’s in northwest London, Britain, July 11, 2014. REUTERS/Suzanne Plunkett/File Photo

But shares in Takeda extended recent losses, tumbling 7 percent as investors fretted over its ability to buy a company twice its size, raising doubts about whether Shire shareholders will accept a bid that is 56 percent in new Takeda shares.

The stock slide – 18 percent since the news of a possible bid broke – makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares.

“While this offer represents a solid improvement over Takeda’s third bid (38 percent cash), we still wonder if it is enough to satisfy Shire shareholders,” said Jefferies analyst David Steinberg.

Shire shares slipped 0.8 percent to 39 pounds by 0850 GMT, well below Takeda’s 49 pounds offer, signaling scepticism about the deal as Takeda’s falling stock price erodes the bid’s $64 billion headline value.

Without a deal, Shire shares could fall back to mid-March levels of 30-32 pounds, pressuring management to find other ways to realize value. Prior to Takeda’s approach, Shire was already considering divestments and a split in its operations.

It is now four weeks since Takeda first revealed it was considering a bid and the absence of firm interest from rivals means investors see only a low chance of an interloper emerging.

The latest development, first reported by Reuters, comes after London-listed Shire rejected four previous offers from Takeda.

The fifth offer is worth 49.01 pounds per share, comprised of 27.26 pounds per share in new Takeda shares and 21.75 pounds per share in cash. That represents a 4.3 percent premium to Takeda’s fourth proposal on April 20 and an 11.4 percent premium to its first approach on March 29.

Shire, a member of Britain’s benchmark FTSE 100 stock index, said its board agreed to extend a Wednesday regulatory deadline to May 8 so Takeda can conduct more due diligence and firm up its bid. Shire added the deadline may be extended further if needed.

Any deal is subject to the resolution of several issues, including completion of due diligence by Shire on Takeda, the Dublin-based company said.

A deal would significantly boost Takeda’s position in gastrointestinal disorders, neuroscience, and rare diseases, including a blockbuster hemophilia franchise.

If successful, it would be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.

Weber, who became Takeda’s first non-Japanese CEO in 2015, has said publicly it was looking for acquisitions to reduce its exposure to a mature Japanese pharmaceutical market.

FILE PHOTO: Takeda Pharmaceutical’s signboard is seen on its headquarters building in Tokyo, Japan January 30, 2018. REUTERS/Kim Kyung-Hoon/File Photo

FINANCIAL STRETCH

The combined company would have its primary listing in Tokyo and also offer American Depository Receipts – a move that would give Shire investors an opportunity to cash out more easily.

But the transaction would be a huge financial stretch, and Takeda investors have been skeptical about the merits of a Shire deal, given the size of the potential purchase and concerns that a large share issue will be needed to fund it.

Moody’s said the deal would pile up debt and hit Takeda’s credit ratings. “This huge acquisition bodes a spike in leverage that could result in a multi-notch downgrade,” said analyst Yukiko Asanuma.

Ambitious cost cutting is also seen as necessary to make the deal pay, and the uncertainties facing an enlarged group would spell a big change in the investment case for holding Takeda.

“Takeda’s shares have been valued for their stability and relatively high dividend,” said Daiwa Securities analyst Kazuaki Hashiguchi, adding this made them attractive even to investors without specialist knowledge of the drug sector.

Takeda, now worth $33 billion by market value, had 466.5 billion yen ($4.3 billion) in cash and short-term investments as of end-December. It said on Wednesday it intended to maintain its dividend policy and investment-grade credit rating following the deal.

Dealmaking has surged in the drug industry this year as large players look to improve their pipelines. A Takeda-Shire transaction would be by far the biggest.

Shire has long been seen as a likely takeover target.

Botox-maker Allergan Plc said last week it was considering making a rival offer, only to scrap it hours later due to pushback from shareholders. Shire was also nearly bought by U.S. drugmaker AbbVie Inc in 2014, until U.S. tax rule changes caused the deal to fall apart.

Shire traces its roots back to 1986, when it began as a seller of calcium supplements to treat osteoporosis, operating from an office above a shop in Hampshire, southern England. Since then, it has grown rapidly through acquisitions to generate revenues of about $15.2 billion last year.

But it has been under pressure in the past 12 months due to greater competition from generic drugs and debt from its $32 billion acquisition of Baxalta in 2016, a widely criticized deal.

It announced last week a sale of its oncology business to unlisted French drugmaker Servier for $2.4 billion.

($1 = 0.7170 pounds)

($1 = 108.8200 yen)

Additional reporting by Ben Hirschler in London, Padraic Halpin in Dublin, Miyoung Kim in Singapore and Sam Nussey in Tokyo; Editing by Mark Potter and Jason Neely

The post Shire willing to back $64 billion Takeda bid, market signals doubts appeared first on World The News.

from World The News https://ift.tt/2Fgraey via News of World

#Daily World News #Daily Entertainment #Daily Sports #Today News #World The News

[dani-qrt]

Shire willing to back $64 billion Takeda bid, market signals doubts

LONDON/NEW YORK/TOKYO (Reuters) – Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year.

FILE PHOTO: Vitamins made by Shire are displayed at a chemist’s in northwest London, Britain, July 11, 2014. REUTERS/Suzanne Plunkett/File Photo

But shares in Takeda extended recent losses, tumbling 7 percent as investors fretted over its ability to buy a company twice its size, raising doubts about whether Shire shareholders will accept a bid that is 56 percent in new Takeda shares.

The stock slide – 18 percent since the news of a possible bid broke – makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares.

“While this offer represents a solid improvement over Takeda’s third bid (38 percent cash), we still wonder if it is enough to satisfy Shire shareholders,” said Jefferies analyst David Steinberg.

Shire shares slipped 0.8 percent to 39 pounds by 0850 GMT, well below Takeda’s 49 pounds offer, signaling scepticism about the deal as Takeda’s falling stock price erodes the bid’s $64 billion headline value.

Without a deal, Shire shares could fall back to mid-March levels of 30-32 pounds, pressuring management to find other ways to realize value. Prior to Takeda’s approach, Shire was already considering divestments and a split in its operations.

It is now four weeks since Takeda first revealed it was considering a bid and the absence of firm interest from rivals means investors see only a low chance of an interloper emerging.

The latest development, first reported by Reuters, comes after London-listed Shire rejected four previous offers from Takeda.

The fifth offer is worth 49.01 pounds per share, comprised of 27.26 pounds per share in new Takeda shares and 21.75 pounds per share in cash. That represents a 4.3 percent premium to Takeda’s fourth proposal on April 20 and an 11.4 percent premium to its first approach on March 29.

Shire, a member of Britain’s benchmark FTSE 100 stock index, said its board agreed to extend a Wednesday regulatory deadline to May 8 so Takeda can conduct more due diligence and firm up its bid. Shire added the deadline may be extended further if needed.

Any deal is subject to the resolution of several issues, including completion of due diligence by Shire on Takeda, the Dublin-based company said.

A deal would significantly boost Takeda’s position in gastrointestinal disorders, neuroscience, and rare diseases, including a blockbuster hemophilia franchise.

If successful, it would be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.

Weber, who became Takeda’s first non-Japanese CEO in 2015, has said publicly it was looking for acquisitions to reduce its exposure to a mature Japanese pharmaceutical market.

FILE PHOTO: Takeda Pharmaceutical’s signboard is seen on its headquarters building in Tokyo, Japan January 30, 2018. REUTERS/Kim Kyung-Hoon/File Photo

FINANCIAL STRETCH

The combined company would have its primary listing in Tokyo and also offer American Depository Receipts – a move that would give Shire investors an opportunity to cash out more easily.

But the transaction would be a huge financial stretch, and Takeda investors have been skeptical about the merits of a Shire deal, given the size of the potential purchase and concerns that a large share issue will be needed to fund it.

Moody’s said the deal would pile up debt and hit Takeda’s credit ratings. “This huge acquisition bodes a spike in leverage that could result in a multi-notch downgrade,” said analyst Yukiko Asanuma.

Ambitious cost cutting is also seen as necessary to make the deal pay, and the uncertainties facing an enlarged group would spell a big change in the investment case for holding Takeda.

“Takeda’s shares have been valued for their stability and relatively high dividend,” said Daiwa Securities analyst Kazuaki Hashiguchi, adding this made them attractive even to investors without specialist knowledge of the drug sector.

Takeda, now worth $33 billion by market value, had 466.5 billion yen ($4.3 billion) in cash and short-term investments as of end-December. It said on Wednesday it intended to maintain its dividend policy and investment-grade credit rating following the deal.

Dealmaking has surged in the drug industry this year as large players look to improve their pipelines. A Takeda-Shire transaction would be by far the biggest.

Shire has long been seen as a likely takeover target.

Botox-maker Allergan Plc said last week it was considering making a rival offer, only to scrap it hours later due to pushback from shareholders. Shire was also nearly bought by U.S. drugmaker AbbVie Inc in 2014, until U.S. tax rule changes caused the deal to fall apart.

Shire traces its roots back to 1986, when it began as a seller of calcium supplements to treat osteoporosis, operating from an office above a shop in Hampshire, southern England. Since then, it has grown rapidly through acquisitions to generate revenues of about $15.2 billion last year.

But it has been under pressure in the past 12 months due to greater competition from generic drugs and debt from its $32 billion acquisition of Baxalta in 2016, a widely criticized deal.

It announced last week a sale of its oncology business to unlisted French drugmaker Servier for $2.4 billion.

($1 = 0.7170 pounds)

($1 = 108.8200 yen)

Additional reporting by Ben Hirschler in London, Padraic Halpin in Dublin, Miyoung Kim in Singapore and Sam Nussey in Tokyo; Editing by Mark Potter and Jason Neely

The post Shire willing to back $64 billion Takeda bid, market signals doubts appeared first on World The News.

from World The News https://ift.tt/2Fgraey via Online News

#World News #Today News #Daily News #Breaking News #News Headline #Entertainment News #Sports news #Sci-Tech

[newsintodays-blog]

Shire willing to back $64 billion Takeda bid, market signals doubts

New Post has been published on https://newsintoday.info/2018/04/25/shire-willing-to-back-64-billion-takeda-bid-market-signals-doubts/

Shire willing to back $64 billion Takeda bid, market signals doubts

LONDON/NEW YORK/TOKYO (Reuters) – Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year.

FILE PHOTO: Vitamins made by Shire are displayed at a chemist’s in northwest London, Britain, July 11, 2014. REUTERS/Suzanne Plunkett/File Photo

But shares in Takeda extended recent losses, tumbling 7 percent as investors fretted over its ability to buy a company twice its size, raising doubts about whether Shire shareholders will accept a bid that is 56 percent in new Takeda shares.

The stock slide – 18 percent since the news of a possible bid broke – makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares.

“While this offer represents a solid improvement over Takeda’s third bid (38 percent cash), we still wonder if it is enough to satisfy Shire shareholders,” said Jefferies analyst David Steinberg.

Shire shares slipped 0.8 percent to 39 pounds by 0850 GMT, well below Takeda’s 49 pounds offer, signaling scepticism about the deal as Takeda’s falling stock price erodes the bid’s $64 billion headline value.

Without a deal, Shire shares could fall back to mid-March levels of 30-32 pounds, pressuring management to find other ways to realize value. Prior to Takeda’s approach, Shire was already considering divestments and a split in its operations.

It is now four weeks since Takeda first revealed it was considering a bid and the absence of firm interest from rivals means investors see only a low chance of an interloper emerging.

The latest development, first reported by Reuters, comes after London-listed Shire rejected four previous offers from Takeda.

The fifth offer is worth 49.01 pounds per share, comprised of 27.26 pounds per share in new Takeda shares and 21.75 pounds per share in cash. That represents a 4.3 percent premium to Takeda’s fourth proposal on April 20 and an 11.4 percent premium to its first approach on March 29.

Shire, a member of Britain’s benchmark FTSE 100 stock index, said its board agreed to extend a Wednesday regulatory deadline to May 8 so Takeda can conduct more due diligence and firm up its bid. Shire added the deadline may be extended further if needed.

Any deal is subject to the resolution of several issues, including completion of due diligence by Shire on Takeda, the Dublin-based company said.

A deal would significantly boost Takeda’s position in gastrointestinal disorders, neuroscience, and rare diseases, including a blockbuster hemophilia franchise.

If successful, it would be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.

Weber, who became Takeda’s first non-Japanese CEO in 2015, has said publicly it was looking for acquisitions to reduce its exposure to a mature Japanese pharmaceutical market.

FILE PHOTO: Takeda Pharmaceutical’s signboard is seen on its headquarters building in Tokyo, Japan January 30, 2018. REUTERS/Kim Kyung-Hoon/File Photo

FINANCIAL STRETCH

The combined company would have its primary listing in Tokyo and also offer American Depository Receipts – a move that would give Shire investors an opportunity to cash out more easily.

But the transaction would be a huge financial stretch, and Takeda investors have been skeptical about the merits of a Shire deal, given the size of the potential purchase and concerns that a large share issue will be needed to fund it.

Moody’s said the deal would pile up debt and hit Takeda’s credit ratings. “This huge acquisition bodes a spike in leverage that could result in a multi-notch downgrade,” said analyst Yukiko Asanuma.

Ambitious cost cutting is also seen as necessary to make the deal pay, and the uncertainties facing an enlarged group would spell a big change in the investment case for holding Takeda.

“Takeda’s shares have been valued for their stability and relatively high dividend,” said Daiwa Securities analyst Kazuaki Hashiguchi, adding this made them attractive even to investors without specialist knowledge of the drug sector.

Takeda, now worth $33 billion by market value, had 466.5 billion yen ($4.3 billion) in cash and short-term investments as of end-December. It said on Wednesday it intended to maintain its dividend policy and investment-grade credit rating following the deal.

Dealmaking has surged in the drug industry this year as large players look to improve their pipelines. A Takeda-Shire transaction would be by far the biggest.

Shire has long been seen as a likely takeover target.

Botox-maker Allergan Plc said last week it was considering making a rival offer, only to scrap it hours later due to pushback from shareholders. Shire was also nearly bought by U.S. drugmaker AbbVie Inc in 2014, until U.S. tax rule changes caused the deal to fall apart.

Shire traces its roots back to 1986, when it began as a seller of calcium supplements to treat osteoporosis, operating from an office above a shop in Hampshire, southern England. Since then, it has grown rapidly through acquisitions to generate revenues of about $15.2 billion last year.

But it has been under pressure in the past 12 months due to greater competition from generic drugs and debt from its $32 billion acquisition of Baxalta in 2016, a widely criticized deal.

It announced last week a sale of its oncology business to unlisted French drugmaker Servier for $2.4 billion.

($1 = 0.7170 pounds)

($1 = 108.8200 yen)

Additional reporting by Ben Hirschler in London, Padraic Halpin in Dublin, Miyoung Kim in Singapore and Sam Nussey in Tokyo; Editing by Mark Potter and Jason Neely

Source link